Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
REGENERELLE is an allogeneic cell therapy product developed by ATVentureCenter (operating under The Crowley Center for Regenerative & Biotherapeutics) consisting of human mesenchymal stem/stromal cells (hMSCs) derived from the Wharton's Jelly of umbilical cords. These cells are intended for use in regenerative medicine to promote tissue repair and modulate inflammation through paracrine signaling and potential cellular differentiation. The product is manufactured as medical-grade material for research use and is being explored for applications in bone repair, wound healing, burn treatment, and anti-aging. While marketed for various regenerative purposes, it has been the subject of FDA regulatory scrutiny regarding its marketing claims and classification as a biological drug product.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on REGENERELLE.